{"id":"amg-301","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL2109249","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AMG 301 works by binding to IL1R1, thereby inhibiting the interleukin-1 (IL-1) signaling pathway. This pathway plays a key role in inflammation and is implicated in various diseases, including certain types of cancer.","oneSentence":"AMG 301 is a monoclonal antibody targeting the interleukin-1 receptor type 1 (IL1R1).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:47.908Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06252649","phase":"PHASE3","title":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-07-17","conditions":"Metastatic Colorectal Cancer","enrollment":450},{"nctId":"NCT03238781","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-09-06","conditions":"Chronic Migraine or Episodic Migraine","enrollment":343}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AMG 301","genericName":"AMG 301","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMG 301 is a monoclonal antibody targeting the interleukin-1 receptor type 1 (IL1R1). Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}